Sandoz Slams Amgen's Injunction Bid In Biosimilar Suit
Sandoz Inc. on Tuesday bashed a bid by Amgen Inc. to block it from marketing its biosimilar version of Amgen's blood treatment Neupogen, saying Amgen hasn't met the requirements for the...To view the full article, register now.
Already a subscriber? Click here to view full article